By: Rong Liu

Although small molecule drugs (< 900 Dalton) are still widely used for different disease indications, large molecule drugs (biologics) have increased exponentially for the treatment of anemia, growth deficiency, diabetes, hepatitis, transplant rejection, cancers, etc. due to new genetic information and better understanding of subcellular cascades and disease processes. What is the fate of a biologic after it is administered to a living organism? How do we determine the concentration of a biologic from the moment that it is administered up to the point at which it is eliminated from the body? Continue reading →